Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Aditi R, Saxena"'
Autor:
John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon L. Lubaczewski, Danna M. Breen, Magdalena A. Harrington, Ira Jacobs, Ruolun Qiu, James Revkin, Michelle I. Rossulek, Aditi R. Saxena
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 1054-1061 (2024)
Abstract Background Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. The
Externí odkaz:
https://doaj.org/article/43771e5cd792467db7f7100408a7e000
Publikováno v:
Obesity Science & Practice, Vol 7, Iss 3, Pp 281-290 (2021)
Abstract Background and Objective Obesity is a chronic disease associated with many serious comorbidities. Pharmacologic therapies are approved for the treatment of obesity; however, short‐term biomarkers to predict weight loss are not well underst
Externí odkaz:
https://doaj.org/article/44f51b6e1dc943ccb5c5f3aaa9647ee7
Autor:
Aditi R. Saxena, Stephanie‐An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P. Esler, Albert M. Kim
Publikováno v:
Diabetes, Obesity and Metabolism. 25:992-1001
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::573fe791dc67dff06094efb2e8eb4af4
https://doi.org/10.1111/dom.14946
https://doi.org/10.1111/dom.14946
Publikováno v:
Clinical Therapeutics. 45:55-70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd604322681bc826297a7fb463b0171e
https://doi.org/10.1016/j.clinthera.2022.12.008
https://doi.org/10.1016/j.clinthera.2022.12.008
Autor:
Ryosuke Ono, Kenichi Furihata, Yoshihiko Ichikawa, Yoshiomi Nakazuru, Arthur Bergman, Donal N. Gorman, Aditi R. Saxena
Publikováno v:
Diabetes, Obesity and Metabolism. 25:805-814
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dc60529b10894dc0f78268a929c1c6a
https://doi.org/10.1111/dom.14928
https://doi.org/10.1111/dom.14928
Autor:
Aditi R, Saxena, Stephanie-An, Lyle, Kaivan, Khavandi, Ruolun, Qiu, Mark, Whitlock, William P, Esler, Albert M, Kim
Publikováno v:
Diabetes, obesitymetabolism.
To assess the safety, tolerability, and pharmacodynamics (PD) of ketohexokinase inhibitor PF-06835919 in participants with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).This double-blind, placebo-controlled, parallel-gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aef06f1c8c4636838f4176ff9ab780c5
https://pubmed.ncbi.nlm.nih.gov/36515213
https://pubmed.ncbi.nlm.nih.gov/36515213
Autor:
Ryosuke, Ono, Kenichi, Furihata, Yoshihiko, Ichikawa, Yoshiomi, Nakazuru, Arthur, Bergman, Donal N, Gorman, Aditi R, Saxena
Publikováno v:
Diabetes, obesitymetabolismREFERENCES.
This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), which is a novel, oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese participants with type 2 diabetes mellit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5334c9bdca29d5d0edb267ea16fd4335
https://pubmed.ncbi.nlm.nih.gov/36433713
https://pubmed.ncbi.nlm.nih.gov/36433713
Autor:
Arthur Bergman, Kristin Chidsey, Aditi R. Saxena, Ryan M. Esquejo, Donal Gorman, Albert M. Kim, David A. Griffith, Clare Buckeridge
Publikováno v:
Nature Medicine. 27:1079-1087
Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e14b7116d32df871d8c577caa40ecc0
https://doi.org/10.1038/s41591-021-01391-w
https://doi.org/10.1038/s41591-021-01391-w
Autor:
David A. Griffith, David J. Edmonds, Jean-Philippe Fortin, Amit S. Kalgutkar, J. Brent Kuzmiski, Paula M. Loria, Aditi R. Saxena, Scott W. Bagley, Clare Buckeridge, John M. Curto, David R. Derksen, João M. Dias, Matthew C. Griffor, Seungil Han, V. Margaret Jackson, Margaret S. Landis, Daniel Lettiere, Chris Limberakis, Yuhang Liu, Alan M. Mathiowetz, Jayesh C. Patel, David W. Piotrowski, David A. Price, Roger B. Ruggeri, David A. Tess
Publikováno v:
Journal of medicinal chemistry. 65(12)
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff991134db369ff3aa7ceaecc2f6263e
https://pubmed.ncbi.nlm.nih.gov/35647711
https://pubmed.ncbi.nlm.nih.gov/35647711
Autor:
RYOSUKE ONO, KENICHI FURIHATA, YOSHIHIKO ICHIKAWA, YOSHIOMI NAKAZURU, ARTHUR BERGMAN, DONAL N. GORMAN, ADITI R. SAXENA
Publikováno v:
Diabetes. 71
Danuglipron is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist shown to reduce plasma glucose and body weight after 28 days of treatment in adults with type 2 diabetes mellitus (T2DM) . This randomized, double-blind (sponsor-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8779e3f381bbbfc2f2cf677cefc2786
https://doi.org/10.2337/db22-339-or
https://doi.org/10.2337/db22-339-or